Compare VIRC & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIRC | NYXH |
|---|---|---|
| Founded | 1950 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 86.1M |
| IPO Year | 1995 | 2021 |
| Metric | VIRC | NYXH |
|---|---|---|
| Price | $6.27 | $0.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.85 |
| AVG Volume (30 Days) | 22.3K | ★ 247.2K |
| Earning Date | 12-07-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $199,652,000.00 | N/A |
| Revenue This Year | N/A | $234.36 |
| Revenue Next Year | $1.23 | $98.45 |
| P/E Ratio | $17.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.16 | $0.80 |
| 52 Week High | $7.46 | $5.92 |
| Indicator | VIRC | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 48.78 | 37.76 |
| Support Level | $5.93 | $0.80 |
| Resistance Level | $6.50 | $0.97 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 58.94 | 57.37 |
Virco Manufacturing Corp is engaged in designing, production and distributing quality furniture for the commercial and education markets. The company manufactures an assortment of products, including mobile tables, mobile storage equipment, desks, computer furniture, chairs, activity tables, folding chairs, and folding tables. Its primary furniture lines are constructed of tubular metal legs and frames, combined with wood and plastic tops, plastic seats and backs, upholstered seats and backs, and upholstered rigid polyethylene and polypropylene shells.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.